Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial

医学 艾博汀阿尔法 贫血 临床终点 内科学 促红细胞生成素 不利影响 透析 人口 随机对照试验 阿尔法 临床试验 肾脏疾病 外科 环境卫生
作者
Ping Zhang,Yan Jiang,Chunping Xu,Linghui Zhou,Hongguang Zheng,Deqiong Xie,Minghao Guo,Xiangyang Huang,Guoyuan Lu,Hongli Jiang,Hongyu Qiu,Bi‐Cheng Liu,Shaomei Li,Qinkai Chen,Yu'ou Xia,Bengui Sun,Xiao Yang,Shiying Zhang,Shutong Du,Mindan Sun
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:65: 102273-102273 被引量:12
标识
DOI:10.1016/j.eclinm.2023.102273
摘要

Background: Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist, is being evaluated as an alternative to epoetin alfa for treating anemia of chronic kidney disease (CKD) in Chinese dialysis patients. There is a critical need for a long-acting, cost-effective erythropoiesis-stimulating agent that does not produce EPO antibodies. Methods: A randomized, open-label, active-comparator, non-inferiority phase three trial was conducted at 43 dialysis centers in China between May 17th, 2019, and March 28th, 2022. Eligible patients aged 18-70 years were randomly assigned (2:1) to receive pegmolesatide once every four weeks or epoetin alfa one to three times per week, with doses adjusted to maintain a hemoglobin level between 10.0 and 12.0 g/dL. The primary efficacy endpoint was the mean change in hemoglobin level from baseline to the efficacy evaluation period in the per-protocol set (PPS) population. Non-inferiority of pegmolesatide to epoetin alfa was established if the lower limit of the two-sided 95% confidence interval for the between-group difference was ≥ -1.0 g/dL. Safety assessment included adverse events and potential anaphylaxis reactions. This trial is registered at ClinicalTrials.gov, NCT03902691. Findings: Three hundreds and seventy-two patients were randomly assigned to the pegmolesatide group (248 patients) or the epoetin alfa group (124 patients). A total of 347 patients (233 in the pegmolesatide group and 114 in the epoetin alfa group) were included in the PPS population. In the PPS, the mean change (standard deviation, SD) in hemoglobin level from baseline to the efficacy evaluation period was 0.07 (0.92) g/dL in the pegmolesatide group and -0.22 (0.97) g/dL in the epoetin alfa group. The between-group difference was 0.29 g/dL (95% confidence interval: 0.11-0.47), verifying non-inferiority of pegmolesatide to epoetin alfa. Adverse events occurred in 231 (94%) participants in the pegmolesatide group and in 110 (89%) in the epoetin alfa group. Hypertension was the most common treatment-related adverse event. No fatal cases of anaphylaxis or hypotension were reported. Interpretation: Monthly subcutaneously injection of pegmolesatide was as effective and safe as conventional epoetin alfa administrated one to three times a week in treating anemia in Chinese dialysis patients. Funding: The study was supported by Hansoh Medical Development Group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老实老虎完成签到,获得积分10
1秒前
1秒前
852的应助被签花采纳,获得10
2秒前
www完成签到,获得积分10
2秒前
刘华强完成签到,获得积分10
3秒前
852的应助被满意莫茗采纳,获得10
3秒前
shi完成签到,获得积分10
3秒前
Juvenilesy的应助被wxy采纳,获得10
3秒前
赘婿的应助被心房的锁采纳,获得30
3秒前
曾业辉发布了新的文献求助20
3秒前
价格发布了新的文献求助10
3秒前
自然朋友完成签到 ,获得积分10
3秒前
卢卡巴尔萨完成签到 ,获得积分10
3秒前
4秒前
宁地啊完成签到 ,获得积分10
5秒前
深情安青的应助被Caboda采纳,获得20
5秒前
美味的屑狐狸完成签到 ,获得积分10
5秒前
Ming Chen完成签到,获得积分10
6秒前
汉堡包的应助被眼睛大花生采纳,获得10
6秒前
7秒前
科目三的应助被luyao970131采纳,获得10
8秒前
8秒前
9秒前
9秒前
大模型的应助被微笑的桐采纳,获得50
9秒前
小贵完成签到,获得积分10
10秒前
10秒前
11秒前
yuan关注了科研通微信公众号
11秒前
kkk发布了新的文献求助10
11秒前
你的完成签到 ,获得积分10
12秒前
归宁发布了新的文献求助10
12秒前
炒栗子发布了新的文献求助20
12秒前
00发布了新的文献求助10
13秒前
脑洞疼的应助被zcm1314521采纳,获得10
16秒前
哈哈完成签到,获得积分10
16秒前
超级盼海完成签到,获得积分10
16秒前
17秒前
18秒前
眉间尺完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172269
求助须知:如何正确求助?哪些是违规求助? 9564976
关于积分的说明 21777545
捐赠科研通 7763871
什么是DOI,文献DOI怎么找? 3431205
关于科研通互助平台的介绍 2555075
邀请新用户注册赠送积分活动 2476246